(Q38247470)

1 September 2017

1 reference

title

FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer (English)

1 reference

1 September 2017

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25204327%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Roy Rabbie

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25204327%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Debashis Sarker

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25204327%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Dionysios Papadatos-Pastos

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25204327%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Paul Ross

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25204327%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

10 September 2014

1 reference

Expert Review of Anticancer Therapy

1 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25204327%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25204327%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25204327%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

1115-1125

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25204327%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

EMT and dissemination precede pancreatic tumor formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcino

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Immunotherapy updates in pancreatic cancer: are we there yet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

Pharmacogenetics of irinotecan toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.957188

10.1586/14737140.2014.957188

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25204327%20AND%20SRC:MED&resulttype=core&format=json

release_ni254ikjs5egrdzkbhbdy57wt4

1 June 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ni254ikjs5egrdzkbhbdy57wt4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference